An interventional study of Dynamometry exam and Walking test in Spondylarthropathy and Sarcopenia, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Screening
Among 12 studies in Spondylarthropathies with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Spondylarthropathies · France.
Among the 12 studies in Spondylarthropathies with a site in France, this one is the only one that started in 2017, is one of 4 with no phase, and was the 9th registered.
68 studies on the registry are indexed under Spondylarthropathies; 10 are open to participants now.
Browse Spondylarthropathies studies →2 of the 12 studies in Spondylarthropathies with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 6–18
University Hospital, Grenoble · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 6 Spondylarthropathies studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is close to the median of 103 across 40 interventional studies indexed under Spondylarthropathies.
Median enrollment 121 across the 9 interventional studies, 489 across the 3 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,867 studies on the registry; 448 are open to participants now.
Hospices Civils de Lyon has 1 study filed under Spondylarthropathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Spondylarthropathies with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it.
The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE).
This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients included in this single group study will have 3 interventions to assess the severity of muscle loss : * dynamometry exam * walking test * Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia \& Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire.
Other: Dynamometry exam · Other: Walking test · Radiation: DXA measurement · Other: SARQOL questionnaire · Behavioral: Life habits Questionnaire
Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
A 4 metres walking test will be performed to assess patient's walking speed
DXA measurement will be performed to assess patient's body composition
Patient's quality of life will be assessed thanks to the SARQOL questionnaire
Life habits Questionnaire
Muscular strength
Muscular strength is the first outcome to evaluate sarcopenia
Time frame: At day 1
Walking speed
Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia
Time frame: At day 1
Muscular mass
Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA
Time frame: Up to 4 month after inclusion
Alcohol consumption
Time frame: At day 1
Tobacco consumption
Time frame: At day 1
Time of sport practice per month
Number of hours of sport practice per month is the first outcome to evaluate patient's global physical activity.
Time frame: At day 1
Physical activity rate in work
Physical activity rate in work can be light, medium, high or not applicable if the patient does not work ; it is the second outcome to evaluate patient's physical global activity.
Time frame: At day 1
Average walking time in a week
Average walking time in a week is the third outcome to evaluate patient's physical global activity.
Time frame: At day 1
Score at the SARQOL questionnaire
Quality of life will be assessed thanks to the SARQOL questionnaire (score between 0 and 100)
Time frame: At day 1
Plan to share: No
Ran from Nov 2017 to primary completion in Jul 2018, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.